EMPACON MET 12.5/500 TABLETS

Product Description

EMPACON MET 12.5/500 TABLETS
Advanced Dual Therapy for Type 2 Diabetes Management

Boost your diabetes care portfolio with EMPACON MET 12.5/500 Tabletsan effective combination of Empagliflozin (12.5 mg) and Metformin Hydrochloride IP (500 mg) designed to improve glycemic control in adults with Type 2 Diabetes Mellitus.

Composition:
Each film-coated tablet contains:
Empagliflozin 12.5 mg
Metformin Hydrochloride IP 500 mg

Key Benefits:
Dual-action formula improves insulin sensitivity and reduces glucose reabsorption
Helps achieve sustained glycemic control with lower risk of hypoglycemia
Supports cardiovascular and renal health in diabetic patients
Convenient once or twice daily oral dosage

Usage:
Recommended as an adjunct to diet and exercise in adults with Type 2 Diabetes Mellitus. Should be prescribed under the supervision of a registered medical practitioner.

Ideal For:
Pharmaceutical wholesalers
Hospital and clinic pharmacies
B2B medical distributors
Institutional and government healthcare procurement